title: Is one year follow-up justified in kala-azar post-treatment?
abstract: Sixty-five patients, 51 males and 14 females, with clinical and parasitological evidence of visceral leishmaniasis were initially treated as follows: 44.6% were on intravenous sodium stibogluconate (pentostam) 20 mg/kg/d for 30 days, 35.4% was on a combination of pentostam as above and allopurinol 21 mg/kg/d in three divided doses for 30 days while 20% was on pentostam 10 mg/kg thrice/d intravenously for 10 days. All patients were parasitologically negative by the end of their respective treatment regimen. All patients were reviewed at 2 months, 6 months, and 12 months periods in order to evaluate the relapse rates and optimal follow-up period. Thirteen patients (20%) relapsed at 2 months and one patient (1.5%) relapsed at 6 months follow-up periods respectively. There was no relapse between 6 months and 12 months follow-up period. The mean liver and spleen sizes in responders showed a dramatic reduction at 2 months follow-up and thereafter a gradual reduction occurred in the next 10 months. Weight gain continued throughout the year. Apart from platelet count which showed a sustained high level from discharge to 12 months follow-up, the peripheral blood indices stabilized from 2 months follow-up. Relapses were retreated until parasitologically negative twice and then followed up, for a period of 12 months. At follow-up the liver and spleen sizes reduced gradually in the next 12 months.(ABSTRACT TRUNCATED AT 250 WORDS)
authors: Clinical Research Centre, Kenya Medical Research Institute, Nairobi.
authors: P M
authors: PM
authors: Nyakundi
authors: K M
authors: KM
authors: Wasunna
authors: J R
authors: JR
authors: Rashid
authors: G S
authors: GS
authors: Gachihi
authors: J
authors: J
authors: Mbugua
authors: G
authors: G
authors: Kirigi
authors: J
authors: J
authors: Muttunga
mesh_terms: D000293:Adolescent; D000328:Adult; D000359:Aftercare; D000493:Allopurinol / Q000627:therapeutic use*; D000967:Antimony Sodium Gluconate / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007898:Leishmaniasis, Visceral / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000493:Allopurinol; D000967:Antimony Sodium Gluconate